相似文献
1
The clinical translation of plasma p-tau217 warrants higher urgency than additional efficacy validation studies.
Alzheimers Dement. 2025 Aug;21(8):e70477. doi: 10.1002/alz.70477.
2
Preoperative Plasma p-tau231, p-tau181, and p-tau217 Are Associated With Postoperative Delirium: A Prospective Study.
J Gerontol A Biol Sci Med Sci. 2025 Jun 10;80(7). doi: 10.1093/gerona/glaf058.
3
Equivalence of plasma and serum for clinical measurement of p-tau217: comparative analyses of four blood-based assays.
medRxiv. 2024 Dec 28:2024.12.26.24319657. doi: 10.1101/2024.12.26.24319657.
4
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment.
JAMA Neurol. 2024 Sep 1;81(9):947-957. doi: 10.1001/jamaneurol.2024.2619.
5
Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease.
Alzheimers Dement. 2025 Feb;21(2):e14502. doi: 10.1002/alz.14502. Epub 2025 Jan 14.
6
Comparison of Plasma p-tau217 and [F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia.
Neurology. 2025 Jan 28;104(2):e210211. doi: 10.1212/WNL.0000000000210211. Epub 2024 Dec 23.
7
Clinical validation of the Lilly SP-X P-tau217 assay: Performance in underrepresented cohorts.
Alzheimers Dement (Amst). 2025 Jun 29;17(3):e70139. doi: 10.1002/dad2.70139. eCollection 2025 Jul-Sep.
8
Temporal Dynamics and Biological Variability of Alzheimer Biomarkers.
JAMA Neurol. 2025 Feb 17;82(4):384-96. doi: 10.1001/jamaneurol.2024.5263.
9
Equivalence of Plasma and Serum for Clinical Measurement of p-tau217: Comparative Analyses of Four Blood-Based Assays.
J Neurochem. 2025 Jul;169(7):e70114. doi: 10.1111/jnc.70114.
10
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum.
Brain. 2025 Jan 29. doi: 10.1093/brain/awaf033.
本文引用的文献
1
Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.
Alzheimers Dement. 2025 Mar;21(3):e70038. doi: 10.1002/alz.70038.
2
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials.
Nat Aging. 2025 May;5(5):883-896. doi: 10.1038/s43587-025-00835-z. Epub 2025 Mar 28.
3
Blood-based biomarkers of Alzheimer's disease and incident dementia in the community.
Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03605-x.
4
Blood biomarkers differentiate AD-related versus non-AD-related cognitive deficits.
Alzheimers Dement. 2025 Mar;21(3):e14619. doi: 10.1002/alz.14619.
5
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
Brain. 2025 Feb 3;148(2):416-431. doi: 10.1093/brain/awae346.
6
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases.
Nat Aging. 2023 Sep;3(9):1079-1090. doi: 10.1038/s43587-023-00471-5. Epub 2023 Aug 31.
7
Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers.
JAMA Netw Open. 2023 Jan 3;6(1):e2252387. doi: 10.1001/jamanetworkopen.2022.52387.
8
Abundance of Nef and p-Tau217 in Brains of Individuals Diagnosed with HIV-Associated Neurocognitive Disorders Correlate with Disease Severance.
Mol Neurobiol. 2022 Feb;59(2):1088-1097. doi: 10.1007/s12035-021-02608-2. Epub 2021 Nov 29.
9
Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
Nat Med. 2021 Jun;27(6):1034-1042. doi: 10.1038/s41591-021-01348-z. Epub 2021 May 24.
Zotero 插件